AR026037A1 - Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos - Google Patents

Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos

Info

Publication number
AR026037A1
AR026037A1 ARP000105395A ARP000105395A AR026037A1 AR 026037 A1 AR026037 A1 AR 026037A1 AR P000105395 A ARP000105395 A AR P000105395A AR P000105395 A ARP000105395 A AR P000105395A AR 026037 A1 AR026037 A1 AR 026037A1
Authority
AR
Argentina
Prior art keywords
preparation
indolinones
medications
replaced
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP000105395A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR026037A1 publication Critical patent/AR026037A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El presente se refiere a indolinonas sustituidas en posicion 5 de la formula general (1) en la que R1 hasta R5 y X están definidos como en lareivindicacion 1, sus isomeros y sus sales, especialmente sus sales fisiologicamente compatibles, quepresent an valiosas propiedades farmacologicas,especialmente un efecto inhibidor sobre diferentes quinasas y complejos de ciclinas y CDKs sobre tirosina-quinasa de receptores, así como sobre laproliferacion de células de tumores, a medicamentos quecontienen estos compuestos, a su utilizacion y a procedimientos para su preparacion.
ARP000105395A 1999-10-13 2000-10-13 Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos Pending AR026037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19949209A DE19949209A1 (de) 1999-10-13 1999-10-13 In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR026037A1 true AR026037A1 (es) 2002-12-26

Family

ID=7925398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105395A Pending AR026037A1 (es) 1999-10-13 2000-10-13 Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos

Country Status (6)

Country Link
EP (1) EP1224169A2 (es)
AR (1) AR026037A1 (es)
AU (1) AU7663100A (es)
CO (1) CO5261507A1 (es)
DE (1) DE19949209A1 (es)
WO (1) WO2001027080A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
BR0215360A (pt) 2001-12-27 2004-12-14 Theravance Inc Derivados de indolina úteis como inibidores de proteìna quinase
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE102004012068A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
DE102004012070A1 (de) 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2016049A1 (en) * 2006-04-24 2009-01-21 Boehringer Ingelheim International GmbH 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
CA3115000A1 (en) * 2018-10-05 2020-04-09 Ichnos Sciences S.A. Indolinone compounds for use as map4k1 inhibitors
CN111285872B (zh) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476307A (en) * 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
WO2001027080A2 (de) 2001-04-19
WO2001027080A3 (de) 2001-11-22
CO5261507A1 (es) 2003-03-31
DE19949209A1 (de) 2001-04-19
AU7663100A (en) 2001-04-23
EP1224169A2 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
AR026036A1 (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos
AR026037A1 (es) Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos
AR025389A1 (es) Indolinonas sustituidas, su preparacion y su empleo como medicamentos
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
ECSP055567A (es) Derivados de indolinona sustituidos en posición 6, su preparación y su uso como medicamentos
ECSP034776A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
MY122357A (en) Indolinones having kinase inhibitory activity
CU20090213A7 (es) Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
ES2196860T3 (es) Nuevas indolinonas sustituidas con efecto inhibidor sobre diferentes cinasas y diferentes complejos ciclina/cdk.
GT200100061A (es) Compuestos y composiciones farmaceuticas y metodos para inhibir kinasas proteinicas.
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
ES2192877T3 (es) 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
MX2010004017A (es) 5-cianotienopiridinas para el tratamiento de tumores.
GT200200190A (es) Compuestos de benzimidazol sustituido y su utilizacion en el tratamiento del cancer
ECSP099562A (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación
UY26988A1 (es) Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos.
CR10225A (es) "compuestos de withacnistina para el tratamiento del cáncer".
UY26390A1 (es) Indolinonas sustituidas en posición 5, su preparación y su utilización como medicamentos